Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Federica Salmi"'
Autor:
Cristina Papayannidis, Stefania Paolini, Barbara Lama, Emanuela Ottaviani, Federica Salmi, Ilaria Iacobucci, Antonio Curti, Daniela Cilloni, Sarah Parisi, Giuseppe Saglio, Renato Fanin, Fortunato Morabito, Maria Pantaleo, Pier Luigi Lollini, Michele Baccarani, Giovanni Martinelli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4094::7b55a66ff847a389db2b76603e100561
http://hdl.handle.net/11585/628633
http://hdl.handle.net/11585/628633
Autor:
Emanuela Ottaviani, Simona Luatti, Federica Salmi, Nicoletta Testoni, Carla Gamberini, Giovanni Martinelli, Giulia Marzocchi, Monica Stacchini, Michele Baccarani, Carmen Baldazzi
Publikováno v:
Leukemia Research. 32:1941-1943
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21d45d565a1324fd05728de8327fcc8c
https://doi.org/10.1016/j.leukres.2008.03.026
https://doi.org/10.1016/j.leukres.2008.03.026
Autor:
Emanuela Ottaviani, Mauro Fiacchini, Federica Salmi, Francesca Palandri, Michele Baccarani, Giovanni Martinelli, Lucia Catani, Nicola Polverelli, Nicola Vianelli
Publikováno v:
Leukemialymphoma. 50(2)
The JAK2(V617F) mutation occurs in 50% of patients with essential thrombocythemia (ET). We investigated the correlation between the JAK2(V617F) mutation and clinical and laboratory characteristics, thrombohemorrhagic risk and incidence of disease evo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3842205edf2af48e0a5a46f6e118ca26
https://pubmed.ncbi.nlm.nih.gov/19235012
https://pubmed.ncbi.nlm.nih.gov/19235012
Autor:
Francesca Palandri, Enrico Derenzini, Emanuela Ottaviani, Nicola Polverelli, Lucia Catani, Federica Salmi, Elena Sabattini, Francesco Bacci, Pier Luigi Zinzani, Michele Baccarani, Nicola Vianelli
Essential Thrombocythemia (ET) is a chronic myeloproliferative disorder (CMPD) characterised by the uncontrolled proliferation of a malignant megakaryocytic clone in absence of prominent bone marro...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e91eb36e56b3f781cff1ea04c1c7d19d
https://hdl.handle.net/11379/569843
https://hdl.handle.net/11379/569843
Autor:
Nicola Vianelli, Federica Salmi, Lucia Catani, Emanuela Ottaviani, Nicoletta Testoni, Antonio De Vivo, Alessandro Lucchesi, Nicola Polverelli, Michele Baccarani, Francesca Palandri, Mauro Fiacchini
Cytotoxic agents like Hydroxyurea, Busulfan and Interferon-alpha are to date the most commonly used therapeutic approaches in Essential Thrombocythemia (ET). However, few data on the efficacy and safety of these agents in the long-term are currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f97399c94ca7f27a34868f3990ce8446
https://hdl.handle.net/11379/569824
https://hdl.handle.net/11379/569824
Autor:
Nicoletta Testoni, Federica Salmi, Pier Paolo Piccaluga, Simona Righi, Claudio Agostinelli, Stefano Pileri, Francesco Bacci, Giovanni Martinelli, Elena Sabattini, Fausto Castagnetti, Stefania Paolini, Brunangelo Falini
Publikováno v:
Leukemia. 23:1370-1371
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cca68f03d6cf3e58cbd22c97301c6a8
https://doi.org/10.1038/leu.2009.95
https://doi.org/10.1038/leu.2009.95
Autor:
Sarah Parisi, Cristina Clissa, Fortunato Morabito, Stefania Paolini, Daniela Cilloni, Michele Baccarani, Emanuela Ottaviani, Renato Fanin, Dino Amadori, Carlo Finelli, Anna Candoni, Nicola Vianelli, Antonio Curti, Giuseppe Saglio, Pier Paolo Piccaluga, Ernesto Vigna, Marco De Gobbi, Giovanni Martinelli, Federica Salmi, Francesco Lauria, Cristina Papayannidis, Barbara Lama, Alfonso Zaccaria, Claudio Laterza, Ilaria Iacobucci
Publikováno v:
ResearcherID
Web of Science
Web of Science
Abstract 1028 Poster Board I-50 Background: Outcome of elderly acute myeloid leukemia (AML) patients is dismal. Targeted-therapies might improve current results by overcoming drug-resistance and reducing toxicity. In particular, the farnesyl-transfer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fcd6cc7eb94c0c394c0335515b5253c
https://doi.org/10.1182/blood.v114.22.1028.1028
https://doi.org/10.1182/blood.v114.22.1028.1028
Autor:
Nicoletta Testoni, Giovanni Martinelli, Panagiota Giannoulia, Emanuela Ottaviani, T. Storlazzi, Daniela Cilloni, Ilaria Iacobucci, Cristina Papayannidis, Federica Salmi, Annalisa Astolfi
Publikováno v:
Journal of Clinical Oncology. 26:7023-7023
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb075ff860a4ad76aded0fd568188ddf
https://doi.org/10.1200/jco.2008.26.15_suppl.7023
https://doi.org/10.1200/jco.2008.26.15_suppl.7023
Autor:
Francesco Lauria, Renato Fanin, Barbara Lama, Ilaria Iacobucci, Giovanni Martinelli, Sarah Parisi, Antonio Curti, Federica Salmi, Giuseppe Saglio, Michele Baccarani, Stefania Paolini, Pier Paolo Piccaluga, Claudio Laterza, Cristina Papayannidis, Cristina Clissa, Alfonso Zaccaria, Fortunato Morabito, Carlo Finelli, Emanuela Ottaviani, Dino Amadori, Nicola Vianelli, Panagiota Giannoulia
Publikováno v:
ResearcherID
Web of Science
Web of Science
Background. Outcome of elderly acute myeloid leukemia (AML) patients is dismal. Tipifarnib (Zarnestra, Z) and Bortezomib (Velcade, V) are new, targeted-treatments that might improve current results. In particular, Z is a farnesyltransferase inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9cfc5e15ba983c61f49931dfa19d593
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000262104703419&KeyUID=WOS:000262104703419
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000262104703419&KeyUID=WOS:000262104703419
Autor:
Alessandra Gnani, Federica Salmi, Fabrizio Pane, Antonella Vitale, Sabina Chiaretti, Nicoletta Testoni, Anna Maria Ferrari, Simona Soverini, Emanuela Ottaviani, Cristina Papayannidis, Stefania Paolini, Francesca Arruga, Annalisa Lonetti, Daniela Cilloni, Ilaria Iacobucci, Giuseppe Saglio, Panagiota Giannoulia, Robert Foa, Giovanni Martinelli, Marco Vignetti, Michele Baccarani, Francesca Paoloni, Pier Paolo Piccaluga, Francesca Messa
Publikováno v:
ResearcherID
Web of Science
Web of Science
Background: BCR-ABL1-positive ALL is the most frequent and prognostically most unfavorable subtype of adult ALL. The main reason for the poor clinical outcome of BCR-ABL1-positive ALL is genetic instability. However, how normal B-cell precursor cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acb8bb96ccef80b51754f18e7f7ca524
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000262104701719&KeyUID=WOS:000262104701719
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000262104701719&KeyUID=WOS:000262104701719